• DiI (DiIC18(3)) Plasma Membrane Probe

  2026-08-13

  DiI (DiIC18(3)) provides orange-red plasma membrane labeling for live or fixed cells and tissues, supporting neuronal tracing, migration, adhesion, fusion, and membrane-associated workflows. It is lipophilic, insoluble in water, and unsuitable for direct aqueous preparation or organelle-specific labeling without additional validation.

• 3X (DYKDDDDK) Peptide: Workflow Guide

  2026-08-13

  Use the 3X (DYKDDDDK) Peptide as a soluble competitor for FLAG-based capture, sensitive detection, and cleaner protein-complex analysis. This guide connects practical 3X FLAG peptide workflows with biofilm research in Synechococcus elongatus, including controls for metal-sensitive assays and structural studies.

• HotStart™ 2X Green qPCR Master Mix for Cell Assays

  2026-08-12

  Learn how HotStart™ 2X Green qPCR Master Mix, SKU K1070, can strengthen gene-expression measurements that complement cell viability and cytotoxicity assays. This scenario-driven guide covers hot-start specificity, assay controls, workflow optimization, data interpretation, and practical reagent selection.

• LSKL, THBS1, and Oxidative Stress in PCOS

  2026-08-12

  The reference study identifies THBS1 inhibition by LSKL as a potential strategy for reducing DHEA-induced oxidative stress and apoptosis in rat granulosa cells. By combining cellular assays, molecular docking, and a PCOS rat model, the work links LSKL activity to restoration of PI3K/AKT signaling, ovarian morphology, estrous cyclicity, and hormone balance.

• SGI-1027: Separating Epigenetic and Lysosomal Effects

  2026-08-11

  SGI-1027 is a DNA methyltransferase inhibitor with a distinctive research opportunity: connecting DNMT inhibition and tumor suppressor gene reactivation with lysosomal cell-death phenotypes. This article presents a mechanism-aware assay strategy grounded in recent renal cancer evidence.

• D2 Receptor Variants and Pathogenic Signaling

  2026-08-11

  This study directly compares two pathogenic DRD2 variants and shows that their clinical differences are better explained by altered constitutive and agonist-induced G-protein signaling than by receptor abundance or arrestin binding alone. The work combines cellular pharmacology, cyclic AMP measurements, thermal stability testing, and molecular dynamics to connect variant position with signaling bias and disease severity.

• Berberrubine and Gut–Liver Metabolism in NAFLD

  2026-08-10

  The reference study identifies berberrubine, a major metabolite of berberine, as an active contributor to protection against diet- and fatty-acid-induced NAFLD models. Its value lies in linking hepatic lipid and glucose regulation with gut microbiota remodeling, while also clarifying which findings remain preclinical and mechanistically associative.

• QX77 Molecular Chaperone Activator Workflow

  2026-08-09

  QX77 provides a chemical route to investigate LAMP2A-linked chaperone-mediated autophagy and Rab11-dependent trafficking in parallel with stem cell differentiation assays. This workflow emphasizes fresh solution handling, time-resolved controls, and careful separation of CMA-related effects from mitochondrial mitophagy mechanisms.

• Ultrasound Nanoparticles Drive Peroxynitrite in Lung Cancer

  2026-08-08

  The reference study develops M@DRSZ, a pH-sensitive, tumor-membrane-coated nanoparticle that combines doxorubicin delivery, nitric oxide release, sonodynamic therapy, and homologous targeting. In A549 lung cancer models, ultrasound activation promoted ROS, NO, and peroxynitrite-associated injury, while treatment also altered tumor immune-cell composition and enhanced tumor suppression.

• Self-Amplifying RNA Influenza Vaccines: Dose-Sparing Evidenc

  2026-08-07

  The reference study identifies self-amplifying RNA as a dose-sparing vaccine modality with particular advantages against influenza B, where conventional mRNA candidates showed weak immunogenicity in mice. Its head-to-head comparison of nucleoside-modified mRNA, self-amplifying RNA, and circular RNA provides a useful framework for separating antigen-design effects from RNA-platform effects.

• MOF Nanoparticle Platform for Synergistic Melanoma Therapy

  2026-08-07

  This study introduces a metal-organic framework (MOF) nanoparticle system co-delivering indocyanine green and a PD-1 inhibitory peptide for combined photothermal and immunotherapy of melanoma. The approach demonstrates glutathione-responsive drug release, effective tumor ablation, and local immune activation, representing a significant advance in cancer nanomedicine.

• ABT-263 (Navitoclax): Optimizing Apoptosis Assays in Cancer

  2026-08-06

  ABT-263 (Navitoclax) empowers researchers to target senescent and chemoresistant cancer cells with precision, as validated by pivotal studies. This guide translates the latest findings and technical insights into actionable workflows, troubleshooting strategies, and comparative advantages for apoptosis and cancer biology research.

• MEK1/2 and c-Myc:MAX Prevent EZH2-Mediated TERT Repression i

  2026-08-06

  This study reveals that MEK1/2 kinases and the c-Myc:MAX complex cooperate to maintain TERT expression in human embryonic stem cells by preventing polycomb (PRC2)-mediated repression. The findings provide new mechanistic insights into telomerase regulation and highlight the central role of epigenetic modifications in pluripotent stem cell biology.

• Ozone Enhances Macrophage Efferocytosis to Relieve Neuropath

  2026-08-05

  This study demonstrates that ozone therapy alleviates neuropathic pain by activating the AMPK/Gas6-MerTK/SOCS3 pathway, which enhances macrophage efferocytosis and reduces neuroinflammation. The mechanistic findings highlight a targeted approach to resolving pain linked to apoptotic cell accumulation, providing a foundation for future pain management strategies.

• SGI-1027: Strategic Epigenetic Modulation in Cancer Research

  2026-08-05

  SGI-1027, a potent DNA methyltransferase inhibitor, is reshaping cancer epigenetics by enabling precise DNA methylation inhibition and robust tumor suppressor gene reactivation. This article delivers a mechanistic deep dive and translational roadmap for researchers, drawing on the latest evidence from gastric cancer models and providing actionable guidance for experimental workflow optimization.

16311 records 1/1088 page Next 12345 下5页 Last page